Congruence Therapeutics

Mutations in the melanocortin receptor (MC4R) gene, leading to protein misfolding and impaired trafficking, are the leading cause of severe early-onset genetic obesity. At Congruence Therapeutics, we are using Revenir™, our in silico drug discovery engine to discover small molecule MC4R correctors which stabilize mutant MC4R, and rescue their trafficking and functional deficits, to offer hope to patients with genetic obesity. Learn more here: https://lnkd.in/gycKfaF8 #Biotech #DrugDiscovery #GeneticObesity #OW2024

Congruence Therapeutics is thrilled to be presenting at ObesityWeek®—the premier conference for obesity research and clinical advances, being held November 3-6, 2024, in San Antonio, TX. We are looking forward to presenting data demonstrating the use of our proprietary platform Revenir™, to discover small molecule MC4R correctors which stabilize mutant MC4R and rescue their trafficking and functional deficits for patients with early-onset genetic obesity.   We are also honored to receive the prestigious Neuroscience Section Blitz Talk Award and look forward to sharing our insights during the highly anticipated Blitz Talks session. Learn more here: https://lnkd.in/gycKfaF8 #Biotech #DrugDiscovery #GeneticObesity #OW2024

The Congruence Therapeutics team is heading to San Antonio, TX, for ObesityWeek® 2024! We're looking forward to connecting with fellow experts, presenting the latest advancements in our MC4R-related early-onset genetic obesity program, and sharing insights into our powerful drug discovery engine, Revenir™. We are also thrilled to have been selected to participate in the Blitz talk Award at this leading obesity conference! We hope to see you there! Learn more about Congruence here: https://lnkd.in/gaKEwTcA #Biotech #DrugDiscovery #GeneticObesity #OW2024

Next week, Indranath Ghosh, Ph.D., our Director of Medicinal Chemistry, will participate in hubXchange's AI in Drug Discovery Xchange Maryland 2024. Dr. Ghosh will lead a roundtable discussion on using AI to reduce the timeline of lead generation to optimization—a game-changing approach in drug discovery.    Learn more here: https://lnkd.in/gv9BT_QZ     #Biotech #Innovation #DrugDiscovery #AI 

#ICYMI. Thank you to the organizers of the 2024 International Congress of Parkinson’s Disease and Movement Disorders Meeting!  The Congruence Therapeutics team was pleased to present preclinical data generated from the deployment of our proprietary platform, Revenir™, to discover GCase correctors for the treatment of Parkinson’s Disease.      Learn more about our platform here: https://lnkd.in/gaKEwTcA   #Biotech #Neuro #MDSCongress #Parkinsons 

We are proud of Lee Fader, Head of Chemistry and resident polymath, for being recognized by KNIME as a power user of their software. In this video, he explains how he coded KNIME to automate data aggregation, visualization and retrieval, making Congruence Therapeutics’ processes seamless and efficient. Keep innovating, Lee!  #Biotech #Innovation #DrugDiscovery #AI 

This weekend, Congruence Therapeutics is presenting at the 2024 International Congress of Parkinson’s Disease and Movement Disorders Meeting, being held September 27-October 1, 2024, in Philadelphia. We are looking forward to presenting data demonstrating the use of our proprietary platform, Revenir, to discover GCase correctors for the potential treatment of Parkinson’s Disease. Come engage with us!   Learn more here: https://lnkd.in/gBiNTX-k #Biotech #Neuro #MDSCongress #Parkinsons

Can AI Solve the Molecule Mysteries that will Unlock Simpler Drug Discovery?   In the latest episode of RBC Capital Markets’ Pathfinders in Biopharma podcast, our CEO, Clarissa Desjardins, joins host Noël Brown and Laksh Aithani, CEO and Co-founder at CHARM Therapeutics, to answer this exciting question.   Tune in to explore the cutting-edge intersection of AI and drug discovery.   Listen now: https://lnkd.in/eJBMwHFc   #drugdiscovery #deeplearning #AI #podcast

Congruence Therapeutics is excited to participate in four investor conferences: the Morgan Stanley 22nd Annual Global Healthcare Conference, the Wells Fargo Annual Healthcare Conference, the 2024 RBC Capital Markets Biotechnology Private Company Virtual Conference, and the 4th Annual Needham & Company Private Biotech Company Virtual 1x1 Forum. More details can be found below: https://lnkd.in/gFe4akey #Biotech #Neuro #MorganStanley2024 #WellsFargo2024 #RBC2024 #Needham2024

For two decades, BIOTECanada’s Gold Leaf Awards have celebrated the outstanding individuals and companies driving innovation and excellence in the Canadian biotechnology sector. We are deeply honored that our CEO has received the prestigious “Game-Changing Industry Leadership Award.” This recognition fuels our commitment to advancing the global biotech industry and making a lasting impact on healthcare and innovation. More details can be found here: https://lnkd.in/eez5Mti6 #Biotech #Innovation #DrugDiscovery #AI #BIOTECanada